161,278 Elevance Health, Inc. $ELV Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 94.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 332,778 shares of the company’s stock after acquiring an additional 161,278 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Elevance Health were worth $129,391,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ELV. Revisor Wealth Management LLC boosted its holdings in shares of Elevance Health by 6.6% in the 3rd quarter. Revisor Wealth Management LLC now owns 4,404 shares of the company’s stock valued at $1,801,000 after purchasing an additional 274 shares during the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Elevance Health by 5.8% during the 3rd quarter. Bank Pictet & Cie Europe AG now owns 1,654 shares of the company’s stock valued at $643,000 after buying an additional 90 shares during the period. 55 North Private Wealth LLC grew its stake in shares of Elevance Health by 4.5% during the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock valued at $233,000 after buying an additional 26 shares during the period. CWA Asset Management Group LLC increased its holdings in shares of Elevance Health by 9.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 823 shares of the company’s stock worth $320,000 after buying an additional 74 shares during the last quarter. Finally, Investment Research Partners LLC acquired a new stake in shares of Elevance Health during the 3rd quarter worth $203,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings were $6.99 per share versus the roughly $4.66–$4.71 consensus estimate, while revenue reached $50.44 billion, above expectations of about $49.22 billion. Earnings also increased from $6.03 per share a year earlier. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: 2026 outlook was raised: Management lifted its underlying earnings baseline to at least $26.75 per share, citing disciplined expense management and better medical-cost performance. Elevance also expects at least 12% adjusted EPS growth in 2027 from the higher earnings base. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon remained a growth driver: Strength in the services business helped offset pressure elsewhere, supporting management’s confidence in future growth. Elevance named Jeff Park president of Carelon, effective December 1, to lead its next expansion phase. Elevance Health Names Jeff Park President of Carelon
• Neutral Sentiment: Elevance declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%. The payout supports shareholder returns but is unlikely to be the primary near-term trading catalyst.
• Negative Sentiment: Membership pressure remains a concern: The earnings beat occurred despite declining medical membership, increasing investor focus on enrollment trends and the company’s ability to sustain growth.
• Negative Sentiment: Although cost management improved, Elevance operates on a thin net margin, and continued medical-cost inflation or weaker enrollment could limit the benefit of the raised forecast. The shares have also recently traded near a 52-week high, potentially increasing profit-taking risk.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ELV. Weiss Ratings reiterated a “hold (c)” rating on shares of Elevance Health in a report on Thursday, August 13th. The Goldman Sachs Group reissued a “neutral” rating and set a $395.00 price target on shares of Elevance Health in a research report on Thursday, July 16th. Leerink Partners upped their price target on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Barclays raised their price objective on Elevance Health from $457.00 to $469.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Royal Bank Of Canada cut their price objective on Elevance Health from $439.00 to $424.00 and set a “sector perform” rating on the stock in a report on Thursday, July 16th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $441.71.

Elevance Health Price Performance

ELV opened at $435.26 on Thursday. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $450.69. The company has a 50 day moving average of $406.59 and a two-hundred day moving average of $389.52. The company has a market cap of $94.39 billion, a P/E ratio of 19.34, a P/E/G ratio of 2.29 and a beta of 0.70. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. The business had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The business’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter last year, the firm posted $6.03 EPS. On average, analysts expect that Elevance Health, Inc. will post 27.20 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s dividend payout ratio is currently 30.58%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.